Expression and clinical significance of LncRNA CBR3-AS1 in multiple myeloma

doi:10.16352/j.issn.1001-6325.2023.06.0948

Abstract

Abstract: Objective To detect the expression level of long non-coding carbonyl reductase 3 antisense RNA1(LncRNA CBR3-AS1) in the serum of patients with multiple myeloma and analyze its clinical significance. Methods This study included 100 patients with multiple myeloma who were first diagnosed in Shijiazhuang People's Hospital from January 2012 to March 2020 as the observation group, and 50 healthy people under the age of 65 who had taken physical examination as the control group. Fluorescence quantitative PCR technology was used to detect the relative expression level of LncRNA CBR3-AS1 in the serum of each group, the relationship between the expression level of serum LncRNA CBR3-AS1 and the clinical parameters of patients with multiple myeloma was analyzed and compared, Kaplan-Meier survival curve was used to analyze the relationship between the expression level of serum LncRNA CBR3-AS1 and the prognosis of patients with multiple myeloma, univariate and multivariate Cox regression were used to assess the factors that may affect the prognosis of patients with multiple myeloma. Results The relative expression level of LncRNA CBR3-AS1 in the serum of the observation group was significantly higher than that of the control group (P＜0.05); The relative expression level of LncRNA CBR3-AS1 in the serum of patients with multiple myeloma was related to clinical Durie-Salmon (D-S) staging and International Staging System (ISS) staging(P＜0.05); Kaplan-Meier survival curve showed that the survival rate of patients in the LncRNA CBR3-AS1 low expression group (78.0%) was significantly higher than that of the patients in the LncRNACBR3-AS1 high expression group (58.0%)(χ²=5.370, P＜0.05); Univariate analysis showed that clinical D-S staging (HR=2.159; 95% CI=1.323-3.524; P＜0.05), ISS staging(HR=1.746; 95% CI=1.091-2.794; P＜0.05) and serum LncRNA CBR3-AS1 expression (HR=1.975; 95% CI=1.210-0.224; P＜0.05) affected the prognosis of patients with multiple myeloma, multivariate Cox regression analysis showed that clinical D-S staging (HR=2.769; 95% CI=1.315-5.832; P＜0.05), ISS staging (HR=2.495; 95% CI=1.117-5.573; P＜0.05) and serum LncRNA CBR3-AS1 expression (HR=3.214; 95% CI=1.206-8.564; P＜0.05) were potential independent influencing factors to development of multiple myeloma. Conclusions Expression of CBR3-AS1 is increased in the serum of patients with multiple myeloma, which may relate to the prognosis of multiple myeloma.

Key words: multiple myeloma, long non-coding carbonyl reductase 3 antisense RNA1(LncRNA CBR3-AS1), clinical parameters, prognostic analysis

CLC Number:

R733.3

ZHANG Yongmei, ZHANG Zhiming, ZHOU Jie, PAN Zhilan, FENG Liqian, YANG Yan. Expression and clinical significance of LncRNA CBR3-AS1 in multiple myeloma[J]. Basic & Clinical Medicine, 2023, 43(6): 948-952.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.06.0948

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I6/948

References 15

[1]	Sevcikova S, Minarik J, Stork M, et al. Extramedullary disease in multiple myeloma-controversies and future directions[J]. Blood Rev, 2019, 36:32-39.
[2]	王雷, 肖砚斌, 康建平, 等. 多发性骨髓瘤治疗现状及方向[J]. 中国继续医学教育, 2019, 11:138-140.
[3]	彭颖, 冯继锋. 长链非编码RNA在常见肿瘤中的研究进展[J]. 中国肿瘤外科杂志, 2020, 12:174-179, 184.
[4]	沈敏, 黄梅. 多发性骨髓瘤中异常表达的长链非编码RNA的作用机制及临床应用研究进展[J]. 山东医药, 2019, 59:109-113.
[5]	刘亮, 刘洪涛, 李医明. LncRNA CBR3-AS1靶向调控miR-5195-3p促进胃癌细胞增殖、迁移及侵袭[J]. 胃肠病学和肝病学杂志, 2021, 30:612-616.
[6]	吕波, 朱新锋, 蔡常春, 等. 长链非编码RNA CBR3-AS1在胆管癌中的表达及其临床意义[J]. 中国普通外科杂志, 2020, 28:960-966.
[7]	Xu L, Zhu H, Gao F, et al. Upregulation of the long non-coding RNA CBR3-AS1 predicts tumor prognosis and contributes to breast cancer progression[J]. Gene X, 2019, 2:100014-100020.
[8]	中国医师协会血液科医师分会, 中华医学会血液学分会, 中国多发性骨髓瘤工作组. 中国多发性骨髓瘤诊治指南(2011年修订)[J]. 中华内科杂志, 2011, 50:892-896.
[9]	史青林, 顾炎, 沈旭星, 等. 修订的国际分期系统对初诊多发性骨髓瘤的预后意义[J]. 临床血液学杂志, 2018, 31:359-364.
[10]	Orlowski RZ, Moreau P, Niesvizky R, et al. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma[J]. Cancer, 2016, 122:2050-2056.
[11]	Carrasco LA, Ezponda T, Meydan C, et al. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma[J]. Leukemia, 2021, 35:1438-1450.
[12]	苑军伟, 吴静, 林静, 等. LncRNA NORAD靶向抑制miR-363-3p对多发性骨髓瘤细胞生物学行为的影响及机制[J]. 临床与病理杂志, 2020, 40:1650-1657.
[13]	贺冠强, 郭敏, 索晓慧, 等. LncRNA TUG1和PCAT-1表达水平与多发性骨髓瘤预后的关系及其诊断价值分析[J]. 国际检验医学杂志, 2021, 42:171-176.
[14]	王涛, 秦涛, 李玉凤. lncRNA FOXD3-AS1在多发性骨髓瘤中的表达及临床意义[J]. 中国临床研究, 2020, 33:733-736.
[15]	Hou M, Wu N, Yao L. LncRNA CBR3-AS1 potentiates Wnt/β-catenin signaling to regulate lung adenocarcinoma cells proliferation, migration and invasion[J]. Cancer Cell Int, 2021, 21:1-12.